Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AYTU BIOPHARMA, INCAYTU · Entity 7560 | Chief Operating Officer | August 11, 2023 | August 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AYTU BIOPHARMA, INC
Report date August 11, 2023 · Filed August 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2033-08-12 | Direct | 7,000 |
Reported balance
After 2023-08-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-11 · Grant · Acquired 7,000 · Balance 7,000 F1: The options vest as follows: 1/3 vest on August 11, 2024, with the remaining options vesting in 24 equal monthly installments, beginning September 11, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest as follows: 1/3 vest on August 11, 2024, with the remaining options vesting in 24 equal monthly installments, beginning September 11, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2023 Filed Aug 15, 2023 23:30 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0000912282-23-000297 · form4.xml · derivative · entry 1 BROOKE CHRISTOPHER · CIK 0001953013 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Shares · 7,000 shares Expires 2033-08-12 F1 · derivative.exercise_date: The options vest as follows: 1/3 vest on August 11, 2024, with the remaining options vesting in 24 equal monthly installments, beginning September 11, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.